rs56875953

Variant summary

Our verdict is Benign. The variant received -15 ACMG points: 0P and 15B. BP4_ModerateBP6_Very_StrongBP7BS2

The NM_021098.3(CACNA1H):​c.1983G>A​(p.Pro661Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000618 in 1,503,902 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.000053 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000063 ( 0 hom. )

Consequence

CACNA1H
NM_021098.3 synonymous

Scores

2

Clinical Significance

Likely benign criteria provided, multiple submitters, no conflicts B:2

Conservation

PhyloP100: 1.37

Publications

1 publications found
Variant links:
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
  • hyperaldosteronism, familial, type IV
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • childhood absence epilepsy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • epilepsy, childhood absence, susceptibility to, 6
    Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -15 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.45).
BP6
Variant 16-1202433-G-A is Benign according to our data. Variant chr16-1202433-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 460055.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=1.37 with no splicing effect.
BS2
High AC in GnomAd4 at 8 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CACNA1HNM_021098.3 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 35 ENST00000348261.11 NP_066921.2 O95180-1B3KQH9

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CACNA1HENST00000348261.11 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 35 1 NM_021098.3 ENSP00000334198.7 O95180-1
CACNA1HENST00000569107.6 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 34 1 ENSP00000454990.2 H3BNT0
CACNA1HENST00000711493.1 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 34 ENSP00000518778.1
CACNA1HENST00000565831.7 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 34 1 ENSP00000455840.1 O95180-2
CACNA1HENST00000711450.1 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 35 ENSP00000518762.1
CACNA1HENST00000564231.6 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 35 1 ENSP00000457555.2 H3BUA8
CACNA1HENST00000638323.1 linkc.1944G>A p.Pro648Pro synonymous_variant Exon 9 of 35 5 ENSP00000492267.1 A0A1W2PR14
CACNA1HENST00000562079.6 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 34 1 ENSP00000454581.2 H3BMW6
CACNA1HENST00000711438.1 linkc.1944G>A p.Pro648Pro synonymous_variant Exon 9 of 34 ENSP00000518754.1
CACNA1HENST00000711482.1 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 36 ENSP00000518771.1
CACNA1HENST00000711485.1 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 35 ENSP00000518774.1
CACNA1HENST00000711455.1 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 36 ENSP00000518768.1
CACNA1HENST00000711483.1 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 35 ENSP00000518772.1
CACNA1HENST00000711456.1 linkc.1983G>A p.Pro661Pro synonymous_variant Exon 9 of 34 ENSP00000518769.1
CACNA1HENST00000621827.2 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 37 6 ENSP00000518766.1
CACNA1HENST00000637236.3 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 34 5 ENSP00000492650.2 A0A1W2PS38
CACNA1HENST00000639478.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 35 5 ENSP00000491945.1 A0A1W2PQW2
CACNA1HENST00000711442.1 linkn.*1430G>A non_coding_transcript_exon_variant Exon 8 of 34 ENSP00000518758.1
CACNA1HENST00000711448.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 36 ENSP00000518760.1
CACNA1HENST00000711449.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 35 ENSP00000518761.1
CACNA1HENST00000711451.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 36 ENSP00000518763.1
CACNA1HENST00000711452.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 36 ENSP00000518764.1
CACNA1HENST00000711453.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 36 ENSP00000518765.1
CACNA1HENST00000711484.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 35 ENSP00000518773.1
CACNA1HENST00000711486.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 37 ENSP00000518775.1
CACNA1HENST00000711487.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 36 ENSP00000518776.1
CACNA1HENST00000711488.1 linkn.1983G>A non_coding_transcript_exon_variant Exon 9 of 35 ENSP00000518777.1
CACNA1HENST00000711442.1 linkn.*1430G>A 3_prime_UTR_variant Exon 8 of 34 ENSP00000518758.1
CACNA1HENST00000640028.1 linkn.1385+598G>A intron_variant Intron 9 of 34 5 ENSP00000491488.1 A0A1W2PQ19

Frequencies

GnomAD3 genomes
AF:
0.0000526
AC:
8
AN:
152220
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000965
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000441
Gnomad OTH
AF:
0.000478
GnomAD2 exomes
AF:
0.0000435
AC:
5
AN:
114840
AF XY:
0.0000329
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000464
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000960
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000704
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000629
AC:
85
AN:
1351682
Hom.:
0
Cov.:
38
AF XY:
0.0000545
AC XY:
36
AN XY:
660664
show subpopulations
African (AFR)
AF:
0.0000977
AC:
3
AN:
30712
American (AMR)
AF:
0.0000307
AC:
1
AN:
32590
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
22754
East Asian (EAS)
AF:
0.000114
AC:
4
AN:
35140
South Asian (SAS)
AF:
0.00
AC:
0
AN:
73340
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
41768
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5486
European-Non Finnish (NFE)
AF:
0.0000712
AC:
75
AN:
1053930
Other (OTH)
AF:
0.0000357
AC:
2
AN:
55962
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.487
Heterozygous variant carriers
0
5
11
16
22
27
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000526
AC:
8
AN:
152220
Hom.:
0
Cov.:
33
AF XY:
0.0000269
AC XY:
2
AN XY:
74362
show subpopulations
African (AFR)
AF:
0.0000965
AC:
4
AN:
41470
American (AMR)
AF:
0.00
AC:
0
AN:
15292
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5190
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10630
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000441
AC:
3
AN:
68020
Other (OTH)
AF:
0.000478
AC:
1
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.550
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000604

ClinVar

Significance: Likely benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Inborn genetic diseases Benign:1
Nov 03, 2019
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Apr 29, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.45
CADD
Benign
15
DANN
Benign
0.85
PhyloP100
1.4

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.070
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs56875953; hg19: chr16-1252433; API